KING PHARMACEUTICALS INC
CIK 1047699 · View on SEC EDGAR ↗
First SEC filing: Oct. 5, 2005 · Latest: Oct. 5, 2005
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 16, 2004 | NVAX | J | 1 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| July 16, 2004 | NVAX | J | 1 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| July 16, 2004 | NVAX | J | 1 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| July 16, 2004 | NVAX | J | 1 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| July 16, 2004 | NVAX | J | 3,775,610 | — | — | 4,100,931 Direct | +1160.58% | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| July 16, 2004 | NVAX | 4% Convertible Senior Note | Common Stock (1,855,014) | $5.30 | Dec. 19, 2007 | 1 | Disposed |
| July 16, 2004 | NVAX | 4% Convertible Senior Note | Common Stock (431,220) | $11.60 | Dec. 19, 2007 | 1 | Disposed |
| July 16, 2004 | NVAX | 4% Convertible Senior Note | Common Stock (574,383) | $8.70 | Dec. 19, 2007 | 1 | Disposed |
| July 16, 2004 | NVAX | 4% Convertible Senior Note | Common Stock (2,297,530) | $8.70 | Dec. 19, 2007 | 1 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.